Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of OptiNose from a buy rating to a hold rating in a research note on Thursday, July 11th. Cantor Fitzgerald reissued a buy rating and issued a $27.00 target price on shares of OptiNose in a research note on Thursday, May 9th. Finally, Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the stock a buy rating in a research report on Tuesday, April 23rd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. OptiNose currently has an average rating of Buy and a consensus price target of $23.30.
OPTN stock traded down $0.46 during midday trading on Thursday, hitting $5.01. The stock had a trading volume of 116,837 shares, compared to its average volume of 239,537. The stock’s 50-day moving average price is $6.75. OptiNose has a 52-week low of $4.95 and a 52-week high of $22.96. The company has a quick ratio of 6.74, a current ratio of 6.95 and a debt-to-equity ratio of 0.79.
Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its holdings in OptiNose by 1,569.2% in the first quarter. BNP Paribas Arbitrage SA now owns 4,006 shares of the company’s stock valued at $41,000 after purchasing an additional 3,766 shares during the last quarter. Stifel Financial Corp purchased a new position in OptiNose during the 4th quarter worth approximately $63,000. Two Sigma Advisers LP purchased a new position in shares of OptiNose during the fourth quarter worth approximately $135,000. Swiss National Bank grew its position in shares of OptiNose by 36.4% during the second quarter. Swiss National Bank now owns 30,700 shares of the company’s stock worth $217,000 after acquiring an additional 8,200 shares during the last quarter. Finally, Bank of America Corp DE grew its position in shares of OptiNose by 31.9% during the fourth quarter. Bank of America Corp DE now owns 53,593 shares of the company’s stock worth $332,000 after acquiring an additional 12,961 shares during the last quarter. 63.68% of the stock is currently owned by institutional investors.
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Further Reading: Moving Average Convergence Divergence (MACD)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.